g Renal disease Prioritisation category Outcome Short-listed by Cost, stakeholder priority Criterion1.1 Serious consequences to the patient Evidence 56 236 – burden DALYs 2011 Criterion 1.1 Serious consequences to the patient Evidence 1.25% – of total DALYs 2011 –% Criterion 1.1 Serious consequences to the patient Score 0.5 – Criterion 1.3 High cost to health system Evidence NHCDC $2.19 billion – – hospital cost Criterion 1.3 High cost to health system Evidence % of 6.49% – – total cost from NCCH Criterion 1.3 High cost to health system Score 1 – Criterion 2.2 Clinician support Evidence Leadership group Established leadership group (Australian and New Zealand Dialysis and – – Transplant Registry) Criterion 2.2 Clinician support Evidence Current clinical Australian and New Zealand Dialysis and Transplantation Registry – – quality registries Criterion 2.2 Clinician support Score 1 – Total score 2.5
g Renal disease Prioritisation category Outcome Short-listed by Cost, stakeholder priority Criterion1.1 Serious consequences to the patient – Evidence burden DALYs 2011 56 236 Criterion 1.1 Serious consequences to the patient – Evidence –% of total DALYs 2011 1.25% Criterion 1.1 Serious consequences to the patient – Score 0.5 Criterion 1.3 High cost to health system – Evidence – NHCDC hospital cost $2.19 billion Criterion 1.3 High cost to health system – Evidence – % of total cost from NCCH 6.49% Criterion 1.3 High cost to health system – Score 1 Criterion 2.2 Clinician support – Evidence – Leadership group Established leadership group (Australian and New Zealand Dialysis and Transplant Registry) Criterion 2.2 Clinician support – Evidence – Current clinical quality registries Australian and New Zealand Dialysis and Transplantation Registry Criterion 2.2 Clinician support – Score 1 Total score 2.5
Prioritised-list-of-clinical-domains-for-clinical-quality-registry-development-Final-report-Nov-2016.docx